Alembic Share Price

Alembic Limited, with its corporate operations in Vadodara, functions as a diversified company engaged in pharmaceutical and real estate businesses. The company was founded in 1907, making it one of India’s oldest pharmaceutical enterprises. Alembic Limited provides a comprehensive range of products through its Active Pharmaceutical Ingredient (API) segment, including fermentation and chemistry-based active pharmaceutical ingredients, and through its Real Estate segment, involving construction of residential and commercial projects, project management, marketing consultancy, and leasing of commercial properties. The company also generates power through co-generation plants and wind power sources.

Alembic share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical and real estate sectors. The company’s financial health depends on demand for pharmaceutical ingredients from drug manufacturers, real estate project execution, API pricing trends, and the performance of its power generation operations. Alembic stock price is influenced by various factors such as earnings, fluctuations in raw material costs, regulatory changes in pharmaceutical manufacturing, and currency exchange rates. In the longer run, strategies such as expanding API manufacturing capabilities, developing new pharmaceutical products, and growing the real estate portfolio affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

Alembic live share price provides real time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Alembic live price helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical and real estate indices. Furthermore, monitoring Alembic stock price movements helps investors understand real time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Alembic Limited Company Fundamentals

a. Company Background

Alembic Limited was founded in 1907 and is headquartered in Vadodara, India. The company is engaged in the business of development, manufacturing, and marketing of pharmaceutical products through its Active Pharmaceutical Ingredients (API) segment, and real estate business through its Real Estate segment. The API business manufactures and markets fermentation and chemistry-based active pharmaceutical ingredients, while the real estate business constructs residential and commercial projects, provides project management and marketing consultancy services, and leases commercial properties. The company also generates power through co-generation plants and wind power sources. Corporate functions are managed from its administrative offices in Vadodara, Gujarat.

b. Company Product Lines

• Active Pharmaceutical Ingredients

• Fermentation-based APIs including penicillin and other antibiotics

• Chemistry-based active pharmaceutical ingredients

• Pharmaceutical Formulations

• Products used in gastroenterology, ophthalmology, orthopaedics, anti-inflammatories, nephrology, cardiology, gynaecology, dermatology, anti-infective, cold and cough, anti-diabetic, and animal health

• Real Estate

• Residential and commercial real estate projects

• Project management and marketing consultancy services

• Leasing of commercial properties

• Power Generation

• Co-generation plants and wind power sources

c. Company Revenue Model

• Domestic Sales

• Revenue generated through API and formulation sales to Indian pharmaceutical companies

• Export Sales

• Contribution from international clients across various countries

• Real Estate Revenue

• Income from construction, leasing, and consultancy services

• Power Revenue

• Revenue from power generation through co-generation plants and wind power sources

d. Geographic Presence

• Global Headquarters

• Primary administrative and management functions based in Vadodara, Gujarat, India

• Manufacturing Facilities

• Three API manufacturing facilities in Gujarat

• Six formulation manufacturing facilities, one of which is in Sikkim

• Export Markets

• Products supplied to international markets depending on demand conditions

e. Key Milestones

• 1907 – Establishment: The company was founded

• 2004 – Stock Exchange Listing: The company was listed on the National Stock Exchange (NSE)

• 2024-2025 – Operational Performance: The company continued its pharmaceutical and real estate operations

f. Industry Perspective

The pharmaceutical and real estate industries are capital intensive and closely linked to demand from healthcare and construction sectors. Demand trends in pharmaceuticals are influenced by healthcare spending, disease prevalence, and regulatory approvals, while real estate demand is driven by economic activity and urbanization. The industries are also affected by fluctuations in raw material prices, regulatory changes, and currency exchange rates. Companies in these sectors must manage manufacturing efficiency, quality standards, and cost control while maintaining operational flexibility. These factors collectively influence financial performance and investor perception of firms like Alembic.

Alembic Limited Stock Market Presence: Listings & Index Representation

Alembic Limited is listed on the National Stock Exchange under the symbol ALEMBICLTD and on the Bombay Stock Exchange with the scrip code 506235. Alembic share price is actively traded on both exchanges. The company’s market presence is within the mid-cap segment of the market. Due to its size and sector focus, Alembic share price is generally tracked by investors interested in the pharmaceutical and real estate industries.

Alembic Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a diversified pharmaceutical and real estate company in India. It finds representation in indices based on its market standing. Alembic stock price is monitored by investors tracking the pharmaceutical and real estate sectors. The company’s presence in these indices helps investors track the stock relative to other pharmaceutical and real estate companies. Alembic stock price is observed by market participants as an indicator of the performance of the pharmaceutical sector in India.

Alembic Limited Stock Performance and Share Price History

Alembic share price today on the NSE reflects its position as a diversified pharmaceutical and real estate company in India. Its performance is qualitatively driven by factors such as API manufacturing output, management of raw material costs, growth in real estate project revenues, and the ability to maintain quality standards. Investors compare Alembic movement with other pharmaceutical and real estate companies to assess relative strength.

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings driven price changes. Broader sector strength has also supported Alembic at certain times. Beyond operational and sector influences, corporate actions such as the company’s expansion into new product categories and real estate projects can significantly affect share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short term swings, even within a regulatory environment influenced by pharmaceutical pricing policies and real estate cycles.

While short term movements respond to events and announcements, longer term valuation trends are better captured by Alembic annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger pharmaceutical demand and stable real estate project execution, whereas a significant low aligns with market corrections or sector volatility. These extremes reflect the impact of global economic conditions, raw material price fluctuations, and earnings visibility, providing a framework for understanding historical performance.

Alembic behaviour mirrors the trading patterns of a diversified company within India’s industrial ecosystem. The company’s diversified portfolio spanning APIs, formulations, real estate, and power generation has shaped its price history. Over the past several years, Alembic shas experienced periods of sharp gains followed by phases of consolidation. Alembic has shown certain volatility patterns reflecting the cyclical nature of its pharmaceutical and real estate operations.

The company’s performance has closely tracked pharmaceutical demand and real estate development cycles. Positive momentum appeared during periods of strong pharmaceutical demand and favourable real estate market conditions. However, periods of weak pharmaceutical pricing and intensified competition have led to consolidation in Alembic. Alembic share price faced selling pressure when raw material costs showed significant increases, reflecting structural challenges in managing input cost volatility in the pharmaceutical sector.

Despite macroeconomic disruptions, Alembic share price showed resilience during recovery phases. While the broader pharmaceutical sector faced supply chain challenges, the company’s diversified business base helped Alembic share price recover from lows. The company maintains a skilled workforce and continues to invest in expanding its manufacturing capabilities.

Alembic share price has declined for several recurring reasons. A drop in pharmaceutical demand or lower API realizations directly impacts revenue visibility and leads to selling pressure. Changes in government policy on pharmaceutical pricing or real estate regulations can also cause Alembic share price to fall. Moreover, increases in operational costs such as raw material prices without matching productivity gains squeeze margins, making Alembic share price less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about demand pipelines, leading to price declines. Alembic share price is sensitive to currency exchange rate movements. Broader market sell offs in pharmaceutical stocks also pull the price down, regardless of the company’s individual performance. Lower client retention or reduced order flow directly hurts revenue, resulting in a lower valuation.

Alembic has seen downward pressure when the company reported fluctuations in profit margins. Alembic movements often mirror broader pharmaceutical sector trends. Alembic can be impacted by changes in raw material costs and client retention rates. Alembic has historically shown sensitivity to regulatory changes. Alembic may also be affected by the company’s ability to maintain its competitive edge in API manufacturing. Alembic performance is closely watched by investors tracking the pharmaceutical segment. Alembic stock price has moved within a range reflecting the broader market correction in pharmaceutical stocks.

Alembic Limited Investor Relevance and Role in Portfolio

Alembic Limited is a holding in pharmaceutical and diversified sector portfolios, offering exposure to active pharmaceutical ingredients, formulations, real estate, and power generation. Its inclusion in major indices underscores its importance in India’s pharmaceutical and real estate space. The company’s position as one of India’s oldest pharmaceutical enterprises, together with its diversified business portfolio and established manufacturing capabilities, makes it a consideration for long term allocations.

Alembic share price is influenced by the company’s ownership structure. The company’s equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. The company’s management includes Malika Chirayu Amin as Managing Director and Chief Executive Officer. This investor base, with stable promoter participation, underscores the company’s role as a holding in both domestic and international portfolios concentrating on pharmaceutical services.

Beyond fundamentals and ownership, Alembic share price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on pharmaceutical demand, real estate project execution, and regulatory policy actions. Alembic stock price is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical and real estate sectors. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements.

Technical indicators provide additional insight into short term momentum shifts in Alembic share price. While these indicators are primarily used for near term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. The company’s financial position reflects its operational performance across business segments.

Overall, Alembic demonstrates a certain volatility profile compared to the broader market, with the stock generally considered to have exposure to sector specific factors such as pharmaceutical demand, raw material costs, and currency fluctuations. Alembic share price is influenced by these factors. Alembic stock price reflects the company’s position in the pharmaceutical and real estate space.

Alembic Limited Sectoral Relevance and Peer Positioning

Alembic Limited sector relevance stems from its century-long presence in the pharmaceutical industry, its position as one of India’s oldest pharmaceutical manufacturers, its portfolio covering fermentation and chemistry-based APIs, pharmaceutical formulations across multiple therapeutic segments, real estate development, and power generation, its manufacturing facilities in Gujarat and Sikkim, its established brand recall among medical professionals, and its status as a diversified company with pharmaceutical and real estate operations. Peer comparisons with companies like Sun Pharmaceutical, Dr. Reddy’s Laboratories, Cipla, Lupin, and Aurobindo Pharma focus on API production capacity, formulation development, and operational scale rather than short term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of pharmaceutical demand, API pricing trends, and regulatory changes further highlights Alembic positioning within the broader pharmaceutical market.

Alembic market cap highlights its position as a player within the pharmaceutical and real estate sectors. The company’s market capitalization has moved in line with investor perceptions of the company’s growth potential following its expansion into new therapeutic areas and real estate projects. From earlier periods through more recent times, the market cap showed trends as the company maintained its manufacturing operations and real estate development activities. This pattern reflects investor confidence during favourable pharmaceutical cycles, followed by consolidation during challenging periods impacted by macroeconomic headwinds. This movement mirrors the correction in Alembic share price from its highs to recent levels.

Alembic earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal years, total income showed trends supported by the core pharmaceutical and real estate businesses. The company’s revenue from operations showed movements supported by demand across various therapeutic segments and real estate project execution. Total income showed variations over the same period. Profit after tax demonstrated operational performance. However, the company has faced headwinds from fluctuating raw material prices, intensified competition, and regulatory changes in pharmaceutical pricing. However, the company has expanded into new therapeutic categories and continues to invest in manufacturing capabilities. These developments illustrate the evolving nature of the pharmaceutical industry and the company’s position within this sector.

Alembic EPS provides insight into its operational performance and income generation from pharmaceutical and real estate activities. The company reported earnings that varied based on pharmaceutical cycles and real estate market conditions. The earnings per share has shown movements over time as the company navigated changing market conditions. The company has a face value per share. More recent quarterly performance suggests that EPS has shown movements as the company benefits from operational efficiency in its manufacturing and real estate segments.

Alembic P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from pharmaceuticals and real estate. The current valuation compared to industry averages indicates how the market assesses the company’s earnings potential. The company’s profit after tax has shown variations across recent fiscal periods based on operational performance. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a dynamic industry undergoing structural transformation. Alembic share price continues to be watched by market participants.

Summary

Alembic Limited, headquartered in Vadodara, operates as a diversified company engaged in the manufacture of active pharmaceutical ingredients, pharmaceutical formulations, real estate development, and power generation. The company, founded in 1907, serves clients across domestic and international markets. Alembic share price reflects market perceptions of the company’s pharmaceutical capabilities and real estate portfolio. Alembic stock price movements are influenced by pharmaceutical demand, raw material costs, and real estate cycles, making it a consideration for investors tracking the pharmaceutical and diversified business sector.